Singapore markets open in 1 hour 2 minutes

Swedish Orphan Biovitrum AB (publ) (SOBI.ST)

Stockholm - Stockholm Real-time price. Currency in SEK
Add to watchlist
272.80-3.00 (-1.09%)
At close: 05:29PM CEST
Full screen
Previous close275.80
Open275.20
Bid273.60 x 0
Ask274.00 x 0
Day's range272.80 - 277.20
52-week range189.03 - 302.00
Volume234,611
Avg. volume443,339
Market cap92.716B
Beta (5Y monthly)0.25
PE ratio (TTM)43.16
EPS (TTM)6.32
Earnings date16 Jul 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est345.30
  • GlobeNewswire

    Sobi to present new myelofibrosis data at the ASCO 2024 Annual Meeting

    WALTHAM, Mass., May 24, 2024 (GLOBE NEWSWIRE) -- Sobi North America, the North American affiliate of Swedish Orphan Biovitrum AB (Sobi®), today announced the presentation of three abstracts that highlights data from its myelofibrosis treatment option at the American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago from May 31 – June 4, 2024. Sobi’s commitment to delivering innovative treatments for people living with hematological diseases is seen in global studies span

  • GlobeNewswire

    Sobi Receives US FDA Fast Track Designation for Emapalumab-lzsg being investigated in Macrophage Activation Syndrome

    WALTHAM, Mass., May 24, 2024 (GLOBE NEWSWIRE) -- Sobi North America, the North American affiliate of Swedish Orphan Biovitrum AB (Sobi®), today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation to emapalumab-lzsg being investigated as a potential therapeutic option in patients with Macrophage Activation Syndrome (MAS). Emapalumab is a fully human, anti-IFNγ monoclonal antibody that binds free and receptor-bound IFNγ, neutralizing its biological activity.

  • PR Newswire

    Positive data from phase 2 NOBLE study of pegcetacoplan presented as late-breaker at ERA congress

    Sobi® and Apellis Pharmaceuticals, Inc. today announced positive one-year results from the phase 2 NOBLE study investigating systemic pegcetacoplan, a targeted C3 therapy, for the treatment of post-transplant recurrence of C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). These data were presented during a late-breaking oral presentation at the European Renal Association (ERA) Congress taking place May 23-26 in Stockholm, Sweden.